Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$13.00
+2.9%
$11.42
$3.98
$13.40
$1.98B1.922.17 million shs1.95 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$28.59
+8.0%
$33.54
$24.28
$55.33
$1.73B2.361.98 million shs1.09 million shs
10x Genomics stock logo
TXG
10x Genomics
$14.30
+9.2%
$12.59
$6.78
$24.76
$1.78B2.033.40 million shs3.45 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$31.00
+5.3%
$26.60
$22.61
$47.32
$2.44B1.972.47 million shs1.05 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
0.00%-0.31%+21.95%+45.58%+182.00%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+1.67%-18.50%+1.17%-35.21%
10x Genomics stock logo
TXG
10x Genomics
0.00%+7.04%+4.15%+75.03%-37.85%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%+2.58%+31.41%+14.14%-1.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.4049 of 5 stars
1.41.00.04.22.01.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1567 of 5 stars
3.42.00.04.44.00.80.6
10x Genomics stock logo
TXG
10x Genomics
3.7237 of 5 stars
2.22.00.04.83.81.70.6
Veracyte, Inc. stock logo
VCYT
Veracyte
2.8348 of 5 stars
3.40.00.04.33.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.88
Moderate Buy$12.38-4.81% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4072.79% Upside
10x Genomics stock logo
TXG
10x Genomics
2.38
Hold$13.54-5.30% Downside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9031.94% Upside

Current Analyst Ratings Breakdown

Latest ADPT, TWST, TXG, and VCYT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
8/12/2025
10x Genomics stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$18.00 ➝ $17.00
8/11/2025
10x Genomics stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$16.00
8/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetUnderweight ➝ Underweight$28.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$14.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$13.00 ➝ $15.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$10.00 ➝ $14.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$13.00 ➝ $15.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M11.06N/AN/A$1.18 per share11.02
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M5.51N/AN/A$7.92 per share3.61
10x Genomics stock logo
TXG
10x Genomics
$610.78M2.91N/AN/A$6.21 per share2.30
Veracyte, Inc. stock logo
VCYT
Veracyte
$445.76M5.47$1.04 per share29.90$15.52 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%N/A
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.3393.9443.06N/A5.50%6.07%5.53%11/5/2025 (Estimated)

Latest ADPT, TWST, TXG, and VCYT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million
8/5/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.84
2.75
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
10x Genomics stock logo
TXG
10x Genomics
N/A
5.84
5.23
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.43
5.10

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
10x Genomics stock logo
TXG
10x Genomics
84.68%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
6.40%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
10x Genomics stock logo
TXG
10x Genomics
9.39%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790152.27 million142.53 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240124.49 million112.80 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.67 million77.57 millionOptionable

Recent News About These Companies

Craig-Hallum Sticks to Its Buy Rating for Veracyte (VCYT)
Craig-Hallum Remains a Buy on Veracyte (VCYT)
Deutsche Bank AG Sells 9,272 Shares of Veracyte, Inc. $VCYT
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Veracyte's Market Outlook Divides Major Investors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.37 (+2.93%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$12.86 -0.14 (-1.08%)
As of 08/22/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$28.59 +2.12 (+8.01%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$28.38 -0.21 (-0.73%)
As of 08/22/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$14.30 +1.20 (+9.16%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$14.43 +0.13 (+0.90%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$31.00 +1.57 (+5.33%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$30.92 -0.09 (-0.27%)
As of 08/22/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.